TransMedics Group, Inc. — Director's Dealing 2019

May 7, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2019-05-06

Reporting Person: Hassanein Waleed H (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-05-06	Common Stock	J	369002	—	Disposed	0	Direct
2019-05-06	Common Stock	J	105429	—	Acquired	105429	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-05-06	Stock Option (Right to Buy)	$16.50	J	16986	Disposed	2020-06-30	Common Stock (4853)	Direct
2019-05-06	Stock Option (Right to Buy)	$57.75	J	4853	Acquired	2020-06-30	Common Stock (4853)	Direct
2019-05-06	Stock Option (Right to Buy)	$0.11	J	781949	Disposed	2021-09-27	Common Stock (223414)	Direct
2019-05-06	Stock Option (Right to Buy)	$0.39	J	223414	Acquired	2021-09-27	Common Stock (223414)	Direct
2019-05-06	Stock Option (Right to Buy)	$0.08	J	900799	Disposed	2023-05-29	Common Stock (257371)	Direct
2019-05-06	Stock Option (Right to Buy)	$0.28	J	257371	Acquired	2023-05-29	Common Stock (257371)	Direct
2019-05-06	Stock Option (Right to Buy)	$0.63	J	798287	Disposed	2027-06-22	Common Stock (228082)	Direct
2019-05-06	Stock Option (Right to Buy)	$0.28	J	228082	Acquired	2027-06-22	Common Stock (228082)	Direct

Footnotes

F1: The Common Stock reported herein as being disposed of is common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement") such common stock of TransMedics, Inc. was converted into shares of common stock of the Issuer on a 3.5-for-one basis.

F2: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F3: The option is fully vested.

F4: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, June 22, 2017.